Menu Search
Equities

Trellus Health PLC

TRLHF:PKC

Trellus Health PLC

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded16.10k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Trellus Health plc is a United Kingdom-based health services company, which is engaged in providing solutions and services for chronic condition management. The Company is focused on chronic costly GI conditions that have high mental health burden, such as inflammatory bowel disease (IBD) which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis. The Company has one division being the providing resilience-driven care for chronic conditions in the inflammatory bowel disease state. The Company’s Trellus Elevate platform is a connected health platform that incorporates the Gaining Resilience Through Transitions (GRITT) methodology and learnings on resilience from clinical research and practice. Trellus Elevate’s personalized health roadmaps include engaging lessons and skill-building techniques designed to empower individuals. The Company’s wholly owned subsidiary is Trellus Health Inc.

  • Revenue in GBP (TTM)43.30k
  • Net income in GBP-5.25m
  • Incorporated2020
  • Employees19.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.